Mucosal delivery of antigen‐coated nanoparticles to lungs confers protective immunity against tuberculosis infection in mice

Mucosal boosting of BCG‐immunised individuals with a subunit tuberculosis (TB) vaccine would be highly desirable, considering that the lungs are the principal port of entry for Mycobacterium tuberculosis (MTB) and the site of the primary infection and reactivation. However, the main roadblock for subunit TB vaccine development is the lack of suitable adjuvants that could induce robust local and systemic immune responses. Here, we describe a novel vaccine delivery system that was designed to mimic, in part, the MTB pathogen itself. The surface of yellow carnauba wax nanoparticles was coated with the highly immunogenic Ag85B Ag of MTB and they were directed to the alveolar epithelial surfaces by the incorporation of the heparin‐binding hemagglutinin adhesion (HBHA) protein. Our results showed that the i.n. immunisation of BCG‐primed BALB/c mice with nanoparticles adsorbed with Ag85B‐HBHA (Nano‐AH vaccine) induced robust humoral and cellular immune responses and IFN‐γ production, and multifunctional CD4+ T cells expressing IFN‐γ, IL‐2 and TNF‐α. Mice challenged with H37Rv MTB had a significantly reduced bacterial load in their lungs when compared with controls immunised with BCG alone. We therefore conclude that this immunisation approach is an effective means of boosting the BCG‐induced anti‐TB immunity.

[1]  M. Paul,et al.  Immune-Complex Mimics as a Molecular Platform for Adjuvant-Free Vaccine Delivery , 2013, PloS one.

[2]  S. Lockhart,et al.  Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial , 2013, The Lancet.

[3]  J. Woof,et al.  A Novel Human IgA Monoclonal Antibody Protects against Tuberculosis , 2011, The Journal of Immunology.

[4]  G. Schoolnik,et al.  A multistage tuberculosis vaccine that confers efficient protection before and after exposure , 2011, Nature Medicine.

[5]  Q. Sattentau,et al.  Carnauba wax nanoparticles enhance strong systemic and mucosal cellular and humoral immune responses to HIV-gp140 antigen , 2011, Vaccine.

[6]  Sylvie Bertholet,et al.  A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis , 2010, Science Translational Medicine.

[7]  M. Tameris,et al.  The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults. , 2010, American journal of respiratory and critical care medicine.

[8]  L. Rocha-Zavaleta,et al.  Adjuvants in tuberculosis vaccine development. , 2010, FEMS immunology and medical microbiology.

[9]  Hongjuan Yu,et al.  Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice. , 2009, Vaccine.

[10]  P. Andersen,et al.  Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T Cells1 , 2009, The Journal of Immunology.

[11]  B. Guy,et al.  The perfect mix: recent progress in adjuvant research , 2007, Nature Reviews Microbiology.

[12]  Mario Roederer,et al.  Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major , 2007, Nature Medicine.

[13]  G. Khuller,et al.  Enhanced immunoprotective potential of Mycobacterium tuberculosis Ag85 complex protein based vaccine against airway Mycobacterium tuberculosis challenge following intranasal administration. , 2006, FEMS immunology and medical microbiology.

[14]  R. Reljic,et al.  Intranasal IFNγ extends passive IgA antibody protection of mice against Mycobacterium tuberculosis lung infection , 2006, Clinical and experimental immunology.

[15]  I. Orme,et al.  Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. , 2006, Vaccine.

[16]  M. Barreto,et al.  Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial , 2005, The Lancet.

[17]  A. Thomas,et al.  Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. , 2005, Vaccine.

[18]  B. Hamasur,et al.  A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab′)2 fragment prolong survival of mice infected with Mycobacterium tuberculosis , 2004, Clinical and experimental immunology.

[19]  Ann Williams,et al.  Protective Effect of a Tuberculosis Subunit Vaccine Based on a Fusion of Antigen 85B and ESAT-6 in the Aerosol Guinea Pig Model , 2004, Infection and Immunity.

[20]  R. G. Hewinson,et al.  Antibody bound to the surface antigen MPB83 of Mycobacterium bovis enhances survival against high dose and low dose challenge. , 2004, FEMS immunology and medical microbiology.

[21]  Mahavir Singh,et al.  Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs , 2004, Immunology.

[22]  H. Alpár,et al.  Immunological Aspects of Polymer Microsphere Vaccine Delivery Systems , 2003, Journal of drug targeting.

[23]  D. Chaplin,et al.  Visualization of Early APC/T Cell Interactions in the Mouse Lung Following Intranasal Challenge1 , 2001, The Journal of Immunology.

[24]  Vincent W. Bramwell,et al.  Microsphere translocation and immunopotentiation in systemic tissues following intranasal administration. , 2001, Vaccine.

[25]  C. Locht,et al.  The heparin-binding haemagglutinin of M. tuberculosis is required for extrapulmonary dissemination , 2001, Nature.

[26]  Stefan H. E. Kaufmann,et al.  Is the development of a new tuberculosis vaccine possible? , 2000, Nature Medicine.

[27]  C. Locht,et al.  Characterization of the Heparin-binding Site of the Mycobacterial Heparin-binding Hemagglutinin Adhesin* , 2000, The Journal of Biological Chemistry.

[28]  E. Unanue,et al.  A mAb recognizing a surface antigen of Mycobacterium tuberculosis enhances host survival. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Appelberg,et al.  Adjuvant modulation of immune responses to tuberculosis subunit vaccines , 1997, Infection and immunity.

[30]  Donna L. Montgomery,et al.  Immunogenicity and protective efficacy of a tuberculosis DNA vaccine , 1996, Nature Medicine.

[31]  H. Weiner,et al.  Peripheral deletion of antigen-reactive T cells in oral tolerance , 1995, Nature.

[32]  R. Reljic,et al.  Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy. , 2009, Tuberculosis.

[33]  C. Locht,et al.  Mycobacterium tuberculosis heparin-binding haemagglutinin adhesin (HBHA) triggers receptor-mediated transcytosis without altering the integrity of tight junctions. , 2006, Microbes and infection.